Point sur le coronavirus Information sur les ventes et approbations

Paris, France et Camberley, Royaume-Uni – 2 juin 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait le point sur son test d’amplification en chaîne par polymérase (PCR) pour COVID-19, mis au point par Primerdesign, la division de diagnostic moléculaire de la société. http://novacyt.com/wp-content/uploads/2020/06/Novacyt-COVID-19-update-02-06-20-FRENCH.pdf

Visit Page

Coronavirus update Sales and regulatory update

Paris, France and Camberley, UK – 2 June 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update on its polymerase chain reaction (PCR) test for COVID-19, developed by Primerdesign, the Company’s molecular diagnostics division. http://novacyt.com/wp-content/uploads/2020/06/Novacyt-COVID-19-update-02-06-20-ENGLISH.pdf

Visit Page

Liquidity Agreement Monthly Update and Total Voting Rights

Paris, France and Camberley, UK – 1 June 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised in

Visit Page